Navigation Links
About 60 Clinical Studies Regarding Schering-Plough's Oncology Compounds Will be Presented at ASCO
Date:5/30/2008

cs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf" target="_new">http://www.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential market and the clinical development of its oncology portfolio. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part I, Item 1A, "Risk Factors" in Schering-Plough's 2008 Q1 10-Q.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
2. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
3. Second Thoughts about Fluoride, Reports Scientific American
4. Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee
5. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
6. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
7. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
8. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
9. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
10. AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
11. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...tatistical significance , , ISELIN, N.J., N...ion (Nasdaq: PARS ) today announced results from...ulsion (NE) drug delivery technology formulated wi...lti-center, randomized, double-blinded, placebo-co...f the Company,s 3% Diclofenac Diethanolamine NanoE...
(Date:11/18/2008)...stCall/ -- NeuroDiscovery Ltd (ASX:,NDL), a speci...pment Company,and Sosei Group Corporation ("Sose...onal biopharmaceutical company, today announce tha...e-clinical efficacy data for NSL-043/SD118.,This ...uropathic pain and has,successfully completed Pha...
(Date:11/18/2008)...diagnosed, elderly AML patients , , PRINCET...uticals today announced that the first patient has...dy of CPX-351 (Cytarabine:Daunorubicin) Liposome I...eloid leukemia (AML). , , The first patient...dical College of Cornell University and New York ...
(Date:11/12/2008)...D. Watson, Marilyn & James Simons and,Sherry Lansi...ov. 12 J. Craig Venter,...er Institute (JCVI), was,awarded the Double Helix ...,November 6th at a gala event in New York City., ...ith Dr. James D.,Watson for making each of their i...
Breaking Medicine Technology:Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 2Sosei and NeuroSolutions Present Further Data on NSL-043/SD118 at the Society for Neuroscience 38th Annual Meeting 3Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 1Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 2Pulmo BioTech Announces Appointment of Chief Financial Officer 5069 3Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 1Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 2Got Fat 3F 3A Plastic Surgeons Review Fat Melting and Fat Grafting Procedures 1960 3Environmental fate of nanoparticles depends on properties of water carrying them 3161 1Environmental fate of nanoparticles depends on properties of water carrying them 3161 2Environmental fate of nanoparticles depends on properties of water carrying them 3161 3Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 1Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 2Thermage a Leading Aesthetic Medical Device Company Announces First Time Exhibitor Status at ACOG Meeting 18263 3
(Date:11/21/2008)...008)The University of Texas Health Science Center ...ellence in Aging Studies (TEXAS), to promote geria...s $2 million award from the Donald W. Reynolds Fou...is will allow us to teach geriatric medicine princ...dent to practicing physicians. With the reach of L...
(Date:11/21/2008)...ain cautious about future antibiotic resistance fr...(HealthDay News) -- People with moderate to severe...be able to reduce the frequency of exacerbations t... a new report says. , The study, published in ...nal of Respiratory and Critical Care Medicine , fo...
(Date:11/21/2008)...21 NursingCenter.com, the premier ...peer reviewed content, has been,updated to improv...tered,users. Powered by Lippincott Williams &...er 900 peer-reviewed continuing education activiti...han 50 leading nursing journals.,Lippincott Willi...
(Date:11/21/2008).... 21 Barr Pharmaceutical...areholders overwhelmingly approved the proposals s...rr by Teva Pharmaceuticals Industries Ltd. (Nasdaq... the overwhelming support of the transaction by th... Chairman and CEO. "We are pleased with the progre...
Breaking Medicine News(10 mins):Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Long-Term Erythromycin Cut COPD Complications 2Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Barr Shareholders Approve Pending Teva Acquisition 2Health News:Barr Shareholders Approve Pending Teva Acquisition 3Health News:Barr Shareholders Approve Pending Teva Acquisition 4
...ncephalopathy (BSE) is the condition in which ther...le. It is very fatal.// The Canadian Food Inspect...he fourth cow was tested positive for this disease...ix-years old. The results of the investigation wer...
...nternational Journal of Cancer on February 17, 200...lon cancer and the level of physical activity in w...erican women has found no such link. Experts felt... the production of prostaglandins and insulin besi...
... organically have better health value. Besides bei... insecticides they increase the nutritional value ...he globe research is being done in this field. P...e harmful chemicals over food surface and cause he...
...rt attack that are commonly referred to as non-com...Indian economy, // claiming approximately $237 of ...es by World Health Organization. While India lost...the toll might reach 60 million due to health rela...
Other Medicine News:Health News:Women, Exercise and Colon Cancer 2
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...e Dual Adaptor allows the surgeon to document proc...eo or 35mm photography. Many different types of ad...
...The ACCU-Beam® line of Surgical Microscope Acc...litters, objective lenses, fiber optic cables, and...ersal Microsurgical Video Adaptor (US pat. no. 5,2...both single-chip and 3CCD cameras on the same adap...
...ALLEGRO Topolyzer and T-CAT have been optimized to...rection and to interact in perfect synchronization...ll necessary treatment and patient parameters are ...GRETTO WAVE laser systems via diskette, mini CD or...
...The WaveScan WaveFront System is an ophthalmic dia...ror and wavefront aberrations of the human eye usi...ents can be used to determine regular (sphero-cyli...rrations) that cause decreased or blurry vision in...
Medicine Products: